How to Buy Denali Therapeutics Stock
Denali Therapeutics Inc
Denali Therapeutics Inc. , a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.
Denali Therapeutics stock last closed at $17.14, up 1.96% from the previous day, and has decreased 33.72% in one year. It has underperformed other stocks in the Biotechnology industry by 0.15 percentage points. Denali Therapeutics stock is currently +17.72% from its 52-week low of $14.56, and -48.54% from its 52-week high of $33.31.
As of May 3, 2024, there are 139.16M shares of DNLI outstanding. The market value of DNLI is $2.39B. In the last 24 hours, 859,792 DNLI shares were traded.
How to Buy Denali Therapeutics Stock
Wondering how to invest in Denali Therapeutics stock? Here's how.
- Choose where to buy Denali Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you decide where to buy Denali Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Choose your payment method and add your details.
- Analyze Denali Therapeutics stock: The Denali Therapeutics ticker symbol is DNLI. Is Denali Therapeutics stock a good investment? Should you buy shares of DNLI? How do DNLI's underlying business fundamentals look? Do top analysts think Denali Therapeutics is a good buy? Why has DNLI's stock price moved recently? (Hint: Our stock analysis website can help you understand if DNLI is a good stock to buy).
- Make your DNLI purchase: Decide if you will purchase DNLI shares at the current market price or use a limit order to purchase DNLI stock at a specific price.
- Watch your investment in DNLI: Create a watchlist to watch your new investment in Denali Therapeutics stock.
Step 1: Choose where to buy Denali Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy DNLI stock.
Our preferred brokerage: eToro
We believe that eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global markets: From Technology to Financial Services, New York to Hong Kong — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro now.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal details so you are able to buy DNLI stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open a new brokerage account.
- Send your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you have created your account on one of the most highly reviewed stock apps, your next step is to transfer the money for your investment:
Watch the video below for more details transferring money into your investment account.
Step 4: Analyze Denali Therapeutics stock
After you have selected the best place to buy Denali Therapeutics stock, it's very important to research their stock prior to investing, so you truly understand the risk as well as the opportunity.
Denali Therapeutics Metrics
DNLI Due Diligence Checks
WallStreetZen was built to help average investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on DNLI's stock page.
Is DNLI stock undervalued or overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge DNLI's intrinsic value.
Using relative valuations metrics:
- DNLI may be undervalued based on its P/B ratio of 2.31x, relative to Biotechnology industry P/B ratio of 6.01x
You can access additional valuation research on DNLI's stock here.
DNLI Financial Health Overview
Positive Financial Indicators:
- Total DNLI debt is lower than 5 years ago, relative to shareholder equity.
- DNLI has $1.03B in cash and short term investments. This is sufficient to cover its annual cash burn of $370.93M.
- There are more short-term assets than short-term liabilities on the DNLI balance sheet.
- DNLI has cash burn of 370930000. It has enough cash and short-term investments to cover this for at least one year.
- DNLI has a low debt to equity ratio of 0.12.
- There are more short-term assets than long-term liabilities on the DNLI balance sheet.
Negative Financial Indicators:
- DNLI profit margin has gone up by 2.57 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Denali Therapeutics stock, according to Wall Street analysts?
Out of 6 Equities analysts who give forecasts on DNLI, the consensus analyst rating on Denali Therapeutics is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
Latest DNLI Analyst Ratings
Jessica Fye, a top 12% analyst from JP Morgan reinstates DNLI with a strong buy rating and announces their DNLI price target of $28.00, on Nov 20, 2023.
You can dive deeper into what analysts are projecting on the Denali Therapeutics stock forecast page.
Metrics for Advanced DNLI Traders
How is DNLI performing as a company?
Last year, DNLI revenue was $330.53M. In the past 5 year, DNLI's revenue has gone up by 20.67% per year. This was slower than the Biotechnology industry average of 29.63%.
Learn more about DNLI's earnings and revenue performance here.
Who is buying/selling DNLI?
Over the last 12 months, insiders at DNLI have sold more shares than they have bought.
Vicki L. Sato, Director of DNLI, was the latest DNLI insider to sell. They sold $30,471.14 worth of DNLI stock on Apr 15, 2024.
Research more about who owns DNLI shares here.
Does DNLI provide a stable income stream?
No, Denali Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about DNLI
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your DNLI purchase
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific price, place a limit order.
Press the Open button and your broker will place the order.
If you need additional assistance buying stocks on eToro, click the helpful video below:
Step 6: Watch your investment in DNLI
Now that you own some shares in DNLI, you'll want to keep up with your investment.
Put DNLI on a watchlist to track the latest developments regarding your DNLI stock.
DNLI Feed
How to Buy Stock in Denali Therapeutics
To reiterate, here are the 6 steps to buy stock in Denali Therapeutics:
- Choose where to buy Denali Therapeutics stock
- Create your brokerage account
- Fund your investment account
- Analyze Denali Therapeutics stock
- Make your DNLI purchase
- Watch your investment in DNLI
If you are looking for a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Denali Therapeutics, create a watchlist on WallStreetZen today.
Other "How To" Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.